Therapeutic Innovation
Novel treatments engineered for long-term patient outcomes.
Built around the business reality of your team.
Patients with unmet needs cannot wait for incremental improvements. We co-invest in programs that change the standard of care — not me-too molecules. Therapeutic innovation at Future Trity means scientific ambition paired with commercial discipline.
Most novel therapies fail not in the lab but in commercialisation: unclear positioning, weak access strategy, and underestimated real-world adherence. We address all three from the start.
A method, not just a capability.
Indication selection grounded in unmet need and payer willingness-to-pay.
Adaptive clinical designs that generate evidence for both regulators and HTA bodies.
Patient-centred endpoints validated with advocacy groups.
Lifecycle planning that protects value through loss of exclusivity.
Clear deliverables, audit-ready documentation.
Co-Development Programs
Risk-shared partnerships from Phase I through registration.
Licensing & In-Licensing
Asset evaluation, deal structuring, and integration support.
Real-World Evidence
Registry design, outcomes research, and HEOR dossiers.
Lifecycle Management
New indications, formulations, and combination strategies.
The difference is in the discipline.
Therapeutic Focus
Concentrated expertise in oncology, immunology, metabolic, and rare disease.
Aligned Incentives
Risk-shared structures mean we win when your patients and shareholders win.
Global Reach
Commercialisation footprint across 92 markets removes launch friction.
Evidence Generation
Integrated medical, market access, and clinical operations.
Have an asset that deserves a serious commercialisation partner? Let's talk.
Our team responds within one business day with a tailored capability brief and next-step proposal.
Brief our Therapeutic Innovation team.
Submissions are reviewed by the capability lead within one business day. All information is treated as confidential under our standard Mutual NDA framework.
Capability lead acknowledges within 24 business hours with a reference number.
Mutual NDA executed prior to detailed technical exchange.
Scoping call with subject-matter experts and a written capability brief.